Regencell Bioscience Holdings Stock Buy Hold or Sell Recommendation
| RGC Stock | USD 5.22 0.48 10.13% |
Considering the 90-day investment horizon and your below-average risk tolerance, our recommendation regarding Regencell Bioscience Holdings is 'Strong Sell'. Macroaxis provides Regencell Bioscience buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding RGC positions. The advice algorithm takes into account all of Regencell Bioscience's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Regencell Bioscience's buy or sell advice are summarized below:
Real Value 4.83 | Hype Value 5.34 | Market Value 5.22 | Naive Value 4.95 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Regencell Bioscience Holdings given historical horizon and risk tolerance towards Regencell Bioscience. When Macroaxis issues a 'buy' or 'sell' recommendation for Regencell Bioscience Holdings, the advice is generated through an automated system that utilizes algorithms and statistical models.
Regencell |
Execute Regencell Bioscience Buy or Sell Advice
The Regencell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regencell Bioscience Holdings. Macroaxis does not own or have any residual interests in Regencell Bioscience Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regencell Bioscience's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regencell Bioscience Trading Alerts and Improvement Suggestions
| Regencell Bioscience generated a negative expected return over the last 90 days | |
| Regencell Bioscience has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (6.06 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from businesswire.com: 2024 US Cannes Lions Young Lions Winners Announced |
Regencell Bioscience Returns Distribution Density
The distribution of Regencell Bioscience's historical returns is an attempt to chart the uncertainty of Regencell Bioscience's future price movements. The chart of the probability distribution of Regencell Bioscience daily returns describes the distribution of returns around its average expected value. We use Regencell Bioscience Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regencell Bioscience returns is essential to provide solid investment advice for Regencell Bioscience.
| Mean Return | -0.72 | Value At Risk | -10.36 | Potential Upside | 10.13 | Standard Deviation | 7.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regencell Bioscience historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regencell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regencell Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regencell Bioscience Holdings backward and forwards among themselves. Regencell Bioscience's institutional investor refers to the entity that pools money to purchase Regencell Bioscience's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2023-12-31 | 16.1 K | Blackrock Inc | 2023-12-31 | 238 | Qube Research & Technologies | 2023-12-31 | 13.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 0.0 | Tower Research Capital Llc | 2023-12-31 | 0.0 |
Regencell Bioscience Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 143.7K | (327.6K) | 6.4M | (4.9M) | (4.4M) | (4.1M) | |
| Free Cash Flow | (844.4K) | (767.3K) | (6.0M) | (5.0M) | (4.5M) | (4.3M) | |
| Net Income | (812.4K) | (1.3M) | (7.6M) | (6.1M) | (5.5M) | (5.2M) | |
| End Period Cash Flow | 387.0K | 59.4K | 6.4M | 1.6M | 1.4M | 1.3M |
Regencell Bioscience Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regencell Bioscience or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regencell Bioscience's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regencell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.77 | |
β | Beta against NYSE Composite | 0.70 | |
σ | Overall volatility | 7.86 | |
Ir | Information ratio | -0.1 |
Regencell Bioscience Volatility Alert
Regencell Bioscience Holdings is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regencell Bioscience's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regencell Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regencell Bioscience Fundamentals Vs Peers
Comparing Regencell Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regencell Bioscience's direct or indirect competition across all of the common fundamentals between Regencell Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regencell Bioscience or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regencell Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regencell Bioscience to competition |
| Fundamentals | Regencell Bioscience | Peer Average |
| Return On Equity | -0.42 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Current Valuation | 56.79 M | 16.62 B |
| Shares Outstanding | 13.01 M | 571.82 M |
| Shares Owned By Insiders | 88.76 % | 10.09 % |
| Shares Owned By Institutions | 0.12 % | 39.21 % |
| Number Of Shares Shorted | 3.94 K | 4.71 M |
| Price To Earning | 26.21 X | 28.72 X |
| Price To Book | 4.12 X | 9.51 X |
| EBITDA | (5.5 M) | 3.9 B |
| Net Income | (6.06 M) | 570.98 M |
| Cash And Equivalents | 59.41 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 463.67 K | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 13.94 X | 2.16 X |
| Book Value Per Share | 0.92 X | 1.93 K |
| Cash Flow From Operations | (4.96 M) | 971.22 M |
| Short Ratio | 0.60 X | 4.00 X |
| Earnings Per Share | (0.45) X | 3.12 X |
| Price To Earnings To Growth | 2.15 X | 4.89 X |
| Number Of Employees | 12 | 18.84 K |
| Beta | -0.35 | -0.15 |
| Market Capitalization | 67.93 M | 19.03 B |
| Total Asset | 12.62 M | 29.47 B |
| Retained Earnings | (17.32 M) | 9.33 B |
| Working Capital | 11.01 M | 1.48 B |
| Current Asset | 438.2 M | 9.34 B |
| Current Liabilities | 551.3 M | 7.9 B |
| Five Year Return | 4.37 % | |
| Net Asset | 12.62 M |
Note: Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 [view details]
Regencell Bioscience Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regencell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Regencell Bioscience Buy or Sell Advice
When is the right time to buy or sell Regencell Bioscience Holdings? Buying financial instruments such as Regencell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 771.3K | 463.7K | 417.3K | 396.4K | Total Assets | 18.0M | 12.6M | 11.4M | 10.8M |
Use Investing Ideas to Build Portfolios
In addition to having Regencell Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Regencell Bioscience Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.